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Abstract              
Context: Quality of life (QoL) and depression are important patient-reported 
outcomes in cancer care. However, the relative importance of depression severity in 
predicting QoL remains unclear due to few methodologically sound studies. 
Objectives: To examine whether depression contributes to impairment of QoL 
irrespective of prognostic factors and symptom burden.                  
Methods: 563 patients were included from the European Palliative Care Research 
Collaborative Study (EPCRC-CSA), an international, multi-centre, cross-sectional 
study. The relative importance of prognostic factors (systemic inflammation (mGPS), 
co-morbidities and physical performance (KPS), symptom burden (loss of appetite, 
breathlessness, nausea (ESAS) and pain (BPI)) and depression severity (PHQ-9) in 
predicting Global Health/QoL (EORTC-QLQ-C30) were assessed using hierarchical 
multiple regression models. 
Results: 55% were females, median age 64 years, 87% had metastatic disease, 
median KPS was 70 and mean global QoL 50.5 (SD=23.3). Worse QoL was 
associated with increased systemic inflammation (mGPS=1 β=-0.12, p=0.003, 
mGPS=2 β=-0.09, p=0.023), lower physical performance (β=0.17, p<0.001), reduced 
appetite (β=-0.15, p<0.001), breathlessness (β=-0.11, p=0.004), pain (β=-0.14, 
p=0.002), and higher depression severity (β=-0.27, p<0.001). The full model 
accounted for 29% of the observed variance in QoL scores. The strongest predictor 
was depression severity, accounting for 5.8% of the variance.   
Conclusion: Depression severity was the strongest single predictor of poorer QoL in 
this sample of patients with advanced cancer, after accounting for a wide range of 
clinically relevant variables. Future studies should investigate the contribution of 
psychosocial variables on QoL. Our findings emphasize the importance of managing 
depression to achieve the best possible QoL for these patients. 
 

















Quality of life (QoL) is becoming an increasingly important factor in cancer care, and 
especially so in palliative care. The World Health Organization defines palliative care 
as “an approach that improves QoL of patients and their families (…) by means of 
early identification and impeccable assessment and treatment of pain and other 
problems (…)”.1 As such, best possible QoL is the main goal of palliative care and 
optimal symptom management the primary means to achieve it. Still, the concept of 
QoL is not defined by WHO, leaving its content open to interpretation. In line with the 
2006 Food and Drug Administration Guideline, we define QoL as “a general concept 
that implies an evaluation of the impact of all aspects of life on general well-being”.2 
The early integration of palliative care services into standard oncology is currently a 
topical issue as reflected by the American Society of Clinical Oncology’s (ASCO) 
Provisional Clinical Opinion.3 Evidence suggests that patients with advanced cancer 
benefit in terms of improved symptom management and enhanced QoL when 
receiving early palliative care.4 With the increased focus on the early integration of 
palliative care into oncology, knowledge of what contributes to good QoL among 
patients with advanced cancer is important in oncology and palliative care. Such 
knowledge aids the early identification of those at risk of poorer QoL, and is useful for 
informing practice and supporting the development of targeted interventions.  
Some studies have identified determinants of QoL in patients with advanced cancer.  
However, these were often performed in quite restricted samples (among patients at 
the very end of life) or after specific treatments (response to radiation therapy for 
painful bone metastases).5 The literature suggests some predictive factors to apply 
across the disease trajectory. Patients with advanced cancer generally experience 
multiple symptoms and decreasing function as the disease progresses6, and  
associations have been reported between poorer QoL and both somatic symptoms 
and decreased physical functioning.7  Other prognostic factors, such as weight loss 
and comorbidities, are also reported to predict QoL.7-10 Systemic inflammation, 
measured by the modified Glasgow Prognostic Score (mGPS), is another prognostic 
factor associated with QoL.11 A recent study found physical functioning and 
increasing systemic inflammation to be associated with worsening of QoL 















Depressive disorders in patients with advanced cancer is common and have an 
average prevalence rate of around 15% based on structured clinical interviews or 
patient-reported measures that include the diagnostic criteria of a depressive 
disorder.12,13 Depression is associated with reduced functional status, lower 
treatment compliance, prolonged hospitalizations and a greater likelihood for a desire 
for hastened death.14,15 Not only does it affect the intensity of physical symptoms, but 
the presence of depression also complicates symptom management.16 Depression in 
patients with advanced cancer is often unrecognized in the clinic, hampering 
adequate treatment.17 
In the general population, depression is consistently found to be a strong predictor of 
impaired QoL.18 We identified very few studies that rigorously investigated this issue 
in people with advanced disease. Firstly, the measurement of depression in patients 
with cancer is challenging, due to the overlap of somatic symptoms of depression 
and progressive cancer. Depression is often assessed by the Hospital Anxiety and 
Depression Scale (HADS),10 but importantly, a review of the HADS as a screening 
tool of major depression reported a widely varying diagnostic accuracy in people with 
a variety of cancers, in line with other studies in patients with advanced cancer.19 
Further, as disease progression is associated with worsening QoL, this should be 
considered when investigating determinants of QoL, yet often disease severity was 
only assessed by functional performance, if it was considered at all.20  
Due to the methodological shortcomings of the studies to date, it remains unclear 
whether depression is contributing to impaired QoL in patients with advanced cancer 
irrespective of symptom burden and other prognostic factors. The aim of the present 
study, which includes a range of relevant disease and treatment variables, is to 
examine whether depression contributes to impairment of QoL. It is hypothesized that 
patients with a poorer prognosis, higher symptom burden and higher depression 
severity also report poorer quality of life than patients with better prognosis, and 
lower symptom burden and depression levels. Moreover, we will explore the relative 
importance of depression severity in predicting QoL in patients with advanced 
cancer.  
Methods 















Data were analysed from a large international cross-sectional study, the EPCRC-
CSA (www.epcrc.org), aiming to improve classification and assessment of symptoms 
in palliative care.21 Patients with advanced cancer were recruited from 17 centers in 
eight countries in 2008 and 2009, including in- and out-patient units, 
hospices/inpatient palliative care beds, general oncology and medical wards. 
Potentially eligible participants were people with: incurable metastatic or locally 
advanced disease; and age 18 years or above. Exclusion criteria were: inability to 
complete the assessment because of language problems, physical incapacity or 
obvious cognitive impairment according to standard clinical criteria. Overall, a 
convenience sample of 1051 eligible participants was recruited.21 Of these, 12 
patients with severe cognitive impairment (Mini-Mental State Exam (MMSE) sum-
score<18)22 were excluded. A further 476 patients were missing one or more of the 
variables of interest in this study and for which a value could not be imputed 
(biomarkers and/or QoL). These patients were therefore excluded. The final sample 
consisted of 563 (53.6%) patients with advanced cancer, all with complete datasets.  
Study measurements 
Health care personnel collected socio-demographic and medical data, while 
participants completed a range of patient-reported instruments. Data collection was 
done directly on touch-sensitive tablet computers.23 
QoL. The Global Health/QoL scale consists of two items evaluating overall health 
(“How would you rate your overall health during the past week?) and QoL (“How 
would you rate your overall quality of life during the past week”) scored on 8-point 
numerical rating scales with 0 being “very poor” and 7 being “excellent”. The scores 
are transformed to a 0-100 score, according the EORTC manual,24 and a higher 
score indicates better Global Health/QoL. This measure has proven useful and 
reliable for assessment of  patients’ self-perceived overall QoL as documented in a 
recent review25 and showed good internal consistency in our sample (Cronbach’s α= 
0.83). 
Medical status: Medical status was assessed based on primary cancer diagnosis 
(breast cancer, pulmonary cancer, gastrointestinal cancer, male genital cancers and 
all others), and current disease status: loco-regionally advanced or metastatic 















Current treatment: Current treatment assessed whether the patients were receiving 
opioids (yes/no), or any oncological treatment: chemotherapy only, other oncological 
treatment (radiotherapy with or without chemotherapy, hormone therapy and/or 
other anti-tumour treatment) or no oncological treatment.  
Prognostic factors. Medical information was retrieved from patient records and health 
care professionals (HCP) registrations. The latter included evaluation of the patients’ 
performance status by the Karnofsky Performance Status (KPS);26 registration of co-
morbidities (heart disease, arthritis, COPD, renal, liver disease and “others”). The 
biomarkers albumin and CRP were either extracted from the patient’s medical record, 
if samples were collected within three days of study-inclusion, or from blood samples 
collected by HCPs and analysed according to local procedures. As a measure of 
systemic inflammation, the biomarkers were combined to calculate the modified 
Glasgow Prognostic Score (mGPS): 0=CRP<10 mg/L; 1= CRP>10mg/L; and 2= 
CRP>10mg/L and albumin<35g/L.27 Self-reported weight change over the last six 
months was also included as a prognostic factor (self-reported weight six months ago 
minus current self-reported weight).  
Symptom burden: “Symptom burden” was measured using three somatic symptoms 
from the Edmonton Symptom Assessment Scale (ESAS)28; nausea, lack of appetite 
and breathlessness. Pain was measured by one question from the Brief Pain 
Inventory (BPI)29; “pain at its worst during the last 24 hours". The ESAS and BPI 
items were all scored on 11-point numerical rating scales with 0 as “no symptom at 
all” and 10 is “worst possible symptom”. Thus, ESAS items on psychological 
symptoms, pain and general well-being/QoL were not included in the analyses due to 
content overlap with depression and overall QoL. 
Depressive symptom severity: Depressive symptoms were assessed using the 
PHQ-9, a self-report questionnaire commonly used in medically ill samples, 
including patients with cancer.13,30 The PHQ-9 items correspond to the DSM-5 
diagnostic criteria for major depressive disorder (MDD) and assess the frequency at 
which they have been bothersome during the past two weeks: 0=“not at all“, 
1=“several days”, 2=“more than half the days” and 3=“nearly every day”. Symptom 
severity, however, is measured by summing the scores on all nine items.31,32 We 















scores on somatic symptoms of depression that commonly overlap with symptoms 
of advanced cancer disease.13 To avoid artificial inflation of any relationships 
between depressive symptoms severity and QoL in this study, we excluded the 
somatic PHQ-9 items and summed the scores on the five non-somatic items 
(depressed mood, anhedonia, feeling of worthlessness, poor concentration and 
thoughts about death/self-harm). Scores ranged from 0-18, with a higher score 
indicating higher depression symptom severity. The PHQ-9 showed acceptable 
internal consistency in our sample (Cronbach’s α= 0.79). 
Statistical methods 
Chi-square, independent group t-tests and Mann-Whitney U tests were used to 
compare differences between groups of patients included and not included in the 
study. Variables to be included in the multivariate models were determined using 
bivariate regression models with statistical significance set at p<0.10. Candidate 
variables were: medical status variables; current treatment variables; prognostic 
factors; symptom burden variables; and depression. Demographic variables were 
controlled for in the multivariate models. Multivariate, hierarchical regression was 
used to explore the relationships between the above-mentioned variables and QoL. 
This method allowed us to estimate the unique variance accounted for in the QoL 
scores by the groups of variables. P-values<0.05 were considered statistically 
significant. Statistical analyses were done using IBM-SPSS 22 (Armonk, NY: IBM 
Corp.). 
Ethical considerations 
The study was performed according to the Helsinki declaration. Ethical approval was 




Sample characteristics and comparisons between those included (n=563) or not 
(n=488) in the sample are provided in Table 1. In brief, those included in the study 
were significantly more likely to be female (p=0.013); Norwegian (p<0.001); to have 
gastrointestinal cancer; but less likely to have breast cancer (p<0.001); to be in-















treatments (p<0.001) or opioids (p<0.001); than those not included (p<0.020). Also, 
the included patients had significantly higher physical functioning scores (KPS, 
p<0.001), lower CRP (p=0.001), higher albumin (p=0.008), lower worst pain 
(p<0.001) and lower depression severity scores (p<0.001, Table 1). There were no 
significant differences in QoL scores, age, marital status and cognitive functioning 
scores (MMSE) between those included and not included. Moreover, about two-thirds 
of the patients were in-patient and one-third were out-patients. However, a patient’s 
in- or out-patient status did not reflect the stages of disease due to organizational 
issues at the different centers and is therefore not included in our analyses.  
Associations with QoL 
Univariate models. The univariate models are presented in Table 2. The 
demographic variables age, gender and marital status were not associated with QoL 
scores. The following variables were significantly associated with a lower QoL score: 
a primary diagnosis of gastrointestinal cancer; receiving chemotherapy only; not 
receiving opioids; factors indicating poor prognosis (a higher mGPS score, lower KPS 
score, weight loss in the last 6 months); and increased symptom burden (more 
nausea and pain, appetite loss and breathlessness, and increased depression 
severity.)   
Multivariate hierarchical model. In the final multivariate model, higher mGPS, lower 
KPS, loss of appetite and more breathlessness and pain, and higher depression 
severity were significantly associated with lower Global Health/QoL scores (Table 2). 
The demographic variables entered in Block 1 were not significantly associated with 
QoL. Medical status variables entered in Block 2 and current treatment variables 
entered in Block 3 accounted for 0.05% (p=0.134) and 6.9% (p<0.001) of the 
variance in QoL scores respectively. Combined, the prognostic factors entered in 
Block 4 accounted for 7.9% (p<0.001) of the observed variance in QoL scores over 
and above the variables entered in Blocks 1-3. Symptom burden variables, entered in 
Block 5, accounted for 9.3% (p<0.001) of the variance in QoL over and above the 
above-mentioned variables. Increased depression severity, entered in Block 6, was 
the strongest single predictor of QoL scores in the model, accounting for 5.8% 
(p<0.001) of the variance in QoL scores over and above that accounted for by all of 















variance in QoL scores. For comparison, we re-ran the model using the total score of 
all nine depression symptoms, including the four somatic symptoms. In this model, 
depression symptom severity accounted for 7.1% of the unique variance of the QoL 
scores. 
Lastly, to investigate how much variance each of the significant predictors explained 
of the QoL scores whilst controlling for all other variables, including depression, we 
ran five separate multiple hierarchical regression models. For each of the five models 
we included in Block 1 all variables but the significant predictor of interest, which was 
included in Block 2. These analyses showed that mGPS explained 1.3% (p=0.006), 
KPS 2.0% (p<0.001), loss of appetite 1.6% (p<0.001), breathlessness 1.0% 
(p=0.004) and worst pain intensity 1.3% (p=0.002) respectively of the variance in QoL 
over and above that explained by all other variables combined.  
 
Discussion 
To our knowledge the present study is the first to tease apart the relative importance 
of treatment related variables, prognostic factors, symptom burden and depression to 
better understand QoL in patients with advanced cancer. The main finding was the 
strong association between depression severity and QoL scores. The model 
explained 29% of the variance in QoL. Depression was the single strongest predictor 
variable in the model, explaining 5.8% of the variance in the QoL scores.  
Depression is prevalent among people with advanced cancer12 and compromises 
QoL10. Although treatable33, it is well documented that both doctors and nurses fail to 
detect emotional distress and patients themselves rarely disclose unless asked.17 
Further, anti-depressive medications are often started too late to have a benefit.34  
Given that the main aim of palliative care is to ensure the best possible QoL1, these 
results emphasize the clinical importance of detecting and treating depression as 
early as possible.  
Combined, the prognostic factors accounted for 7.6% of the variance in the QoL 
scores. Both increased systemic inflammation and poorer physical performance 
status remained significantly associated with poorer QoL in the multivariate models, 
confirming their importance for QoL in populations with advanced diseases.7,8 















age, gender, marital status or highest level of education were not associated with 
QoL scores in our sample. The literature on the importance of sociodemographic 
variables for QoL among advanced cancer patients is inconclusive. Some studies 
report no or only minimal effects of demographic variables. For example, Lundh and 
colleagues found that being married was associated with lower QoL, while Jordhoy 
and colleagues found no influence from a live-in partner.8,36 In line with our findings, it 
seems that the overall influence of sociodemographic characteristics on QoL 
amongst severely diseased patients is superseded by their disease status.8  
To avoid artificially conflating the relationship between depression severity and QoL, 
we used a modified depression measure that included only the emotional and 
cognitive symptoms of depression. It is therefore hard to compare the reported 
depression severity and levels of QoL in our sample with those found in the existing 
literature. However, the prevalence rate for major depression defined according to 
the DSM-V diagnostic criteria in the present sample was 11%. This is similar to that 
reported in a meta-analysis of studies diagnosing major depression based on 
structured clinical interviews (14.3% (95%CI: 11.1 – 17.9).12  The mean QoL score of 
50.5 is comparable to that reported in similar patient groups.37 The corresponding 
numbers for the general population are 5-6% and 75, for depression38 and QoL39, 
respectively.  
Study strengths and limitations 
The study’s cross-sectional design prevents us from making claims of causality 
between the variables. Further, as our model focuses on disease and treatment, 
psychosocial variables, such as social support which are likely to contribute to QoL 
were not included. In addition, associations between some variables may be 
conflated due to the common method of measurement used, i.e. common-method 
variance. However, excluding the somatic symptoms from our depression measure 
and including objective indicators of prognosis and observer-rated measures of 
physical functioning, which is rarely done in research to date, should reduce this 
problem. Further, due to ethical regulations, we lack information about patients who 
were not invited or declined participation. Additionally, our sample reported 
significantly higher KPS scores and lower levels of systemic inflammation, loss of 















severely affected patients are not likely to be included in our sample. In line with this, 
the depression prevalence reported on a slightly different part of the EPCRC-CSA 
sample was somewhat greater than the 11% reported here.13 Further, our measure 
of depression is based on self-report rather than on a diagnostic interview. 
Nevertheless, the PHQ-9 corresponds to the criteria used in the gold standard (the 
SCID-MDD interview) and is recommended as a screening tool for depression by 
ASCO.40 Lastly, data were collected during 2008 and 2009. As such, current 
treatments may potentially produce slightly different symptom profiles than those 
described in our sample. However, we do not think this would have influenced the 
results in any way, as the patients had advanced, incurable disease. 
Strengths of this study are that it represents a large international sample of patients 
with advanced cancer. Second, the sample is well characterized on a broad range of 
clinically relevant variables. The sample’s heterogeneity therefore strengthens the 
generalizability of our observational design. Many studies do not differentiate 
between signs and symptoms of disease burden, despite the defined distinction 
between a subjective experience and an objective indicator.41 Hence, these results 
add to the literature by suggesting that subjective symptoms and objective indicators 
of disease burden contribute to impaired QoL.  
In this large, well characterized sample of patients with advanced cancer, we found 
that the depression severity had by far the strongest association with patients’ QoL, 
irrespective of disease factors, prognostic factors and symptom burden. As such, our 
findings are a reminder of the importance of attending to psychological symptoms 
plays in the care of advanced cancer patients. There is a need for improvement in 
our efforts to detect and treat depressive symptoms. 
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Table 1. Sample characteristics comparing those included in the study n=563 vs those not included, n=488. 





Continuous variables Median range n Median Range N p 
Age  63.0 18-89 563 64.0 22-98 488 0.541 
MMSE
2 
 29.0 18-30 563 29.0 10-30 457 0.571 
KPS  70.0 20-100 563 70.0 20-100 475 <0.001 
CRP  12.0 1-436 563 25.0 0.8-431 189 0.001 
Total number co-mobidities
3
 1.0 0-4 563 1.0 0-6 485 0.555 
ESAS: Nausea 0.0 0-10 563 0.0 0-10 462 0.360 
ESAS: Loss of appetite 3.0 0-10 563 3.0 0-10 460 0.006 
ESAS: Breathlessness 1.0 0-10 563 1.0 0-10 460 0.346 
Worst pain intensity
4
 2.0 0-10 563 4.0 0-10 448 <0.001 
Depression symptom severity
5 
2.0 0-15 563 3.0 0-15 406 0.004 
Global Health status/QoL 50.0 0-100 563 50.0 0-100 404 0.465 
  Included Not included    
Categorical variables N % n %    
Gender        0.013 
   Female  248 44.0% 261 53.5%    
   Male  315 56.0% 227 46.5%    
Nationality         
  Norwegian  366 65.0% 154 31.6%   <0.001 
  Not Norwegian
 
197 35.0% 343 68.4%    
Marital status:       0.84 
 Married/de facto  373 66.3% 315 64.9%    
 Not married/divorced/single  190 33.7% 170 35.1%    
Setting:        <0.001 
  In-patient   385 68.4% 213 43.8%    
  Out-patient 178 31.6% 273 56.2%    
Primary Cancer Diagnosis:      0.001 
  Gastrointestinal tract 171 30.4% 103 21.4%    
  Pulmonary  100 17.8% 74 15.4%    
  Breast  74 13.1% 103 21.4%    
  Male genital organs  & prostate
 
59 10.5% 55 11.4%    
  Other
6 
 159 28.2% 147 30.5%    
Current disease status
7
:         
  Metastatic  485 86.1% 402 82.9%   0.017 
  Loco-regionally advanced 78 13.9% 83 17.1%    
Current treatment:       
  Chemotherapy only 265 47.1% 173 35.7%   <0.001 
  Other oncological treatments
8 
141 25.0% 85 17.5%    
  None 157 27.9% 227 46.8%    
     Opioids  291 33.5% 314 40.3%   <0.001 
mGPS
9 
        
0  263 47% 45 -    
1  154 27% 33 -    













Notes. Abbreviations: KPS = Karnofsky performance scale, where 100=normal functioning and 0=dead.
  
1
Mann-Whitney U, chi-square and difference in proportions (Z) tests. 
2
MMSE Mini Mental State Exam 
3
Co-morbidities: Heart disease, Arthritis, COPD, renal- and liver disease and other.
  
4
Scored on a 0-10 numerical rating scale: 0 = “No pain”, 10 = “Pain as bad as you can imagine in the last 24 hrs”. 
5
Depression severity = sum score of all non-somatic symptoms (depressed mood, anhedonia, guilt, trouble 
concentrating and suicidal ideations), range 0-15). 
6
 Other cancers includes (included vs not-included%): urinary cancers (6,4 vs 4,9%), skin cancers incl. malignant 
melanomas (4,6 vs. 3,1%), leukaemia/lymphoma (3,7 vs. 5,7%), secondary/ill-defined malignant tumours 
(2,8%), malignant connective / soft tissue tumours (2,7 vs. 3,9%), head and neck (2,5 vs. 3,5%), gynaecological 
(2,1 vs. 4,1%), tumours of the CNS (1,8 vs. 1,0%), malignant endocrine tumours (1,1 vs. 0,6%), multiple primary 
cancers (0,2 vs. 1,0%)), malignant bone tumours (0,4 vs. 0,2%). 
7





 Other oncological treatments include: radiotherapy without or with chemotherapy, hormone therapy and/or 
other anti-tumour treatments 
9 
mGPS scores were not compared between those included and not due to large number of missing values for 
those not included.  
 















Table 2. Univariate and hierarchical multivariate regression models predicting Global Health/ QoL. Only 
univariate predictors (except demographic characteristics) with p<0.10 are included in the multivariate 
regression model. Standardised beta values are shown. Significance levels are indicated as explained below. 
Reference categories are provided in the notes.  
  Univarite Multivariate 
 Model Steps  1 2 3 4 5 6 
1 Demographics:        
Gender
1 
-0.02 -0,04 -0,03 -0,02 -0,03 -0,05 -0,02 
Age
2 
0.06 0,05 0,05 0,08 0,08 0,05 0,04 
Maritalstatus
3 
0.01 0,02 0,02 0,05 0,05 0,03 0,03 
2 Medical Status:        
Diagnosis
4 
   BC vs all others 0.07 0,09 0,06 0,04 0,06 0,04 
   Pulm. vs all others 0.04 0,04 0,03 0,04 0,10* 0,07 
   GI vs all others 0.12* 0,12* 0,07 0,08 0,10* 0,08 
   Male gen. vs all     
others 0.07 0,07 0,09 0,09 0,09 0,06 
Total comorbidities
 
-0.04 - - - - - 
3 Current treatment:
5 
Chemo only  0.20*** 0,18** 0,09 0,07 0,07 
Other oncol. treat.  0.01 0,05 0,06 0,03 0,05 
Opioides -0.25*** -0,18*** -0,09* 0,00 0,01 
4 Prognostic factors:
6 
       
mGPS 1 -0,17***    -0,15*** -0,12** -0,12** 
  mGPS 2 -0,25***    -0,16*** -0,11** -0,09* 
KPS 0.29*** 0.23*** 0,18*** 0,17*** 
 Weight change 0.09*    0,02 -0,02 -0,03 
5 Symptom Burden:
7 
       
 Nausea -0.16***     0,00 0,03 
 Loss of appetite  -0.32***     -0,18*** -0,15** 
Breathlessness -0.21*** -0,13** -0,11** 
Worst pain intensity -0.33** -0,18*** -0,14** 






adj. -0.001 0.005 0.069 0.142 0.232 0.290 
Note. Significance levels indicated by: *<0.05, **<0.01, ***<0.001.  
1
Male (vs female); 
2
Age categorised in decades: 18-27, 28-37, 38-47, 48-57, 58-67, 68-77, 78-87, 88-100 
3
Married/de facto vs. not married/divorced/single. 
4
Diagnoses: All other diagnoses (vs. Gastro Intestinal cancer (GI), pulmonary cancers (Pulm.), breast cancer 




treatments: Chemotherapy vs not receiving chemotherapy, all other treatments vs not receiving 














Prognostic factors: mGPS - modified Glasgow Prognostic Score, KPS – Karnofsky Performance Status; Weight 
change: (self-reported weight six months ago) – (current self-reported weight) 
7
Symptom burden: Nausea, loss of appetite and breathlessness were measured by ESAS. Worst pain severity 
during the last 24 hours by the Brief Pain Inventory. Higher scores indicate higher symptom burden. 
 
8
Depression severity = sum score of all non-somatic items (depressed mood, anhedonia, guilt, trouble 
concentrating and suicidal ideations) 
 
 
 
